Kami Maddocks
Ohio State University Comprehensive Cancer Center · Ohio State University
Built from public records under this name as ClinicalTrials.gov spells it. A name can belong to more than one person, so each section says how its rows were tied to this name. No contact details are shown.
Trials
Studies that name Kami Maddocks as principal investigator, study chair or study director, newest first. Live from ClinicalTrials.gov, fetched 2026-11-12 06:55 UTC. Open this list on ClinicalTrials.gov
- Ph1/Ph2NCT03583424 · Venetoclax, Carmustine, Etoposide, Cytarabine, and Melphalan Before Stem Cell Transplant in Treating Participants With Relapsed or Refractory Non-Hodgkin LymphomaOhio State University Comprehensive Cancer Center · completed · Hematopoietic Cell Transplantation Recipient, Recurrent Diffuse Large B-Cell Lymphoma, Recurrent Grade 1 Follicular Lymphoma · principal investigator
- Ph2NCT03478514 · Phase II Palbociclib +Ibrutinib in Mantle Cell LymphomaAlliance Foundation Trials, LLC. · active not recruiting · Mantle Cell Lymphoma, B Cell Lymphoma · study chair
- Ph1NCT02950220 · Pembrolizumab and Ibrutinib in Treating Patients With Relapsed or Refractory Non-Hodgkin LymphomaKami Maddocks · completed · B-Cell Lymphoma, Unclassifiable, With Features Intermediate Between Diffuse Large B-Cell Lymphoma and Classical Hodgkin Lymphoma, Grade 1 Follicular Lymphoma, Grade 2 Follicular Lymphoma · principal investigator
- Ph1NCT02049541 · Study of BKM120 & Rituximab in Patients With Relapsed or Refractory Indolent B-Cell LymphomaKami Maddocks, MD · completed · Extranodal Marginal Zone B-cell Lymphoma of Mucosa-associated Lymphoid Tissue, Nodal Marginal Zone B-cell Lymphoma, Recurrent Grade 1 Follicular Lymphoma · principal investigator
- Ph2NCT01589302 · PCI-32765 (Ibrutinib) in Treating Patients With Relapsed or Refractory Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma, or B-cell Prolymphocytic LeukemiaKami Maddocks, MD · active not recruiting · Prolymphocytic Leukemia, Recurrent Small Lymphocytic Lymphoma, Refractory/Relapsed Chronic Lymphocytic Leukemia · principal investigator
- Ph1NCT01479842 · Rituxan/Bendamustine/PCI-32765 in Relapsed DLBCL, MCL, or Indolent Non-Hodgkin's LymphomaKami Maddocks, MD · active not recruiting · Extranodal Marginal Zone B-cell Lymphoma of Mucosa-associated Lymphoid Tissue, Nodal Marginal Zone B-cell Lymphoma, Recurrent Adult Diffuse Large Cell Lymphoma · principal investigator
Grants
NIH projects from RePORTER, fetched 2026-11-12 06:55 UTC. A project is listed only when its grant number is on one of the trials above, or when the awardee institution matches an affiliation the registry gives for this name. Coverage is US federal funding only; UK and EU funders are not searched yet.
- Protocol Review and Monitoring SystemP30CA016058 · NCI · OHIO STATE UNIVERSITY · fiscal years 2026 · $70,201 awarded in 2026Grant number is on one of their registry trials
Most cited trial papers
Clinical-trial papers with this author name, ranked by citations from NIH iCite, fetched 2026-11-12 06:55 UTC. The ranking covers the 200 most relevant of 39 PubMed records, and a shared surname and initials can bring in a namesake. All 39 on PubMed
- Ibrutinib is an irreversible molecular inhibitor of ITK driving a Th1-selective pressure in T lymphocytes.Blood · 2013704 citationsRCR 17.9
- Tafasitamab plus lenalidomide in relapsed or refractory diffuse large B-cell lymphoma (L-MIND): a multicentre, prospective, single-arm, phase 2 study.Lancet Oncol · 2020475 citationsRCR 19.8
- BTKC481S-Mediated Resistance to Ibrutinib in Chronic Lymphocytic Leukemia.J Clin Oncol · 2017435 citationsRCR 12.6
- Ibrutinib enhances chimeric antigen receptor T-cell engraftment and efficacy in leukemia.Blood · 2016412 citationsRCR 11.5
- Ibrutinib treatment improves T cell number and function in CLL patients.J Clin Invest · 2017344 citationsRCR 9.7
- 118 citationsRCR 3.3
- 118 citationsRCR 3.4
- Phase IIa study of the CD19 antibody MOR208 in patients with relapsed or refractory B-cell non-Hodgkin's lymphoma.Ann Oncol · 2018114 citationsRCR 3.5
- Long-term outcomes from the Phase II L-MIND study of tafasitamab (MOR208) plus lenalidomide in patients with relapsed or refractory diffuse large B-cell lymphoma.Haematologica · 2021114 citationsRCR 6.1
- 100 citationsRCR 2.8